CA-CONVIVA
11.8.2021 15:02:06 CEST | Business Wire | Press release
The streaming explosion, which hit its apex during the Covid-induced lockdowns in Q2 2020, is here to stay according to new data from Conviva, the intelligence cloud for streaming media. Conviva’s Q2 2021 State of Streaming report revealed streaming viewing time worldwide grew 13% in Q2 2021, as compared to Q2 2020. Despite a 7% decline in streaming viewing in April, North America still saw a 2% increase in streaming viewing in Q2 2021, compared to the same time last year. Other regions saw even bigger spikes in time spent streaming with Africa growing 79% and South America growing 192% year over year driven by the launch of new services.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210811005256/en/
In tandem with increased viewership, the quality of streaming ads also improved significantly in Q2 2021. Only 16% of ads represented missed opportunities as they went unfilled or failed to play as expected, down from 37% the previous quarter. While total ad attempts dropped 8% from Q1 to Q2 2021, more attempts were successful, resulting in a 4% increase overall in ad impressions. What’s more, in Q2 2021, viewers had a better experience with ads as they spent 31% less time waiting for ads to play and ad duration decreased 3% to 27 seconds.
“As the global streaming industry grows and competition becomes even more intense, consumer expectations for a superior streaming experience – premium content, consistent performance and high-quality ad creative – will only continue to rise,” said Keith Zubchevich, CEO, Conviva. “The publishers and advertisers that can meet or exceed these expectations will be rewarded with continued growth; however, failing to address any aspect of the viewing experience could spell disaster.”
Device Fragmentation; Roku Still Dominates
Big screens, including connected TV devices, smart TVs and gaming consoles, remained the dominant way to stream in Q2 2021, commanding 73% of global viewing time, down just 1% from Q2 2020 even as consumers spent less time home bound. Mobile phones captured that 1% share, growing from 10% in Q2 2020 to 11% in Q2 2021. While smart TVs continued their meteoric rise, up 46%, and connected TV devices saw moderate growth, up 5%, gaming consoles were the lone big screen streaming device to tally a significant decrease, down 14%. Among connected TV devices, Roku maintained its dominance with 31% global share of big screen viewing time, but dropped slightly in share as smart TV-only devices including Samsung TV, LG TV, Android TV, and Vizio TV each increased 1-2%.
Top Streaming Shows Being Discussed on Social
Streaming services are beginning to realize the immense value of social platforms as they promote their content and engage with consumers. Grey’s Anatomy, which promotes its streaming availability on Hulu, had the most cross-platform engagements on social media in Q2 2021, closely followed by Netflix’s Spanish-language drama Elite. Among new originals, Loki claimed the top social engagement spot for Disney+ at number four on Conviva’s list of the top streaming shows by social media engagement. Netflix was the streaming service most successfully driving engagements for its shows on social media with six shows noted on the list, followed by The CW with four of the top 25 shows.
The Fortune 500 and Social Videos
In addition to advertising on linear and streaming, the largest companies in the world continue to leverage video on social platforms as a way to engage with their customers. According to a Conviva analysis of the Fortune 500, McDonald’s, Netflix, Nike, Apple and Facebook all claimed top social spots in Q2 2021. Netflix tallied the most social media videos, most video views and highest total cross-platform engagements, while Apple had the highest average engagements per video and highest average engagements per post for the quarter. McDonald’s collaboration with the K-pop group BTS drove millions of engagements in Q2 2021, securing it the top spot for average cross-platform engagement rate for any brand with more than fifteen thousand followers.
To download the full report, visit: www.conviva.com/state-of-streaming
Methodology
Data for Conviva’s State of Streaming report was primarily collected from Conviva’s proprietary sensor technology currently embedded in 3.3 billion streaming video applications, measuring in excess of 500 million unique viewers watching 180 billion streams per year with nearly 2 trillion real-time transactions per day across more than 180 countries. Year-over-year comparisons were normalized at the customer level for accurate representations of industry growth. The social media data consists of data from over 2000 accounts, over 5 million posts, 12.5 billion video views and over 35 billion engagements across Facebook, Instagram, Twitter and YouTube.
About Conviva
Conviva is the intelligence cloud for streaming media. Powered by our patented Stream Sensor™ and Stream ID™, our real-time platform enables marketers, advertisers, technology teams and customer care teams to build, engage and monetize their audiences. Conviva is dedicated to supporting brands like CCTV, DAZN, Disney+, Hulu, Paramount+, Peacock, Sky, Sling TV, TED and WarnerMedia as they unlock the incredible opportunity in streaming media. Today our platform processes nearly 2 trillion streaming data events daily, supporting more than 500 million unique viewers watching 180 billion streams per year across 3.3 billion applications streaming on devices. Conviva ensures digital businesses of all sizes can stream better—every stream, every screen, every second. To learn more, visit www.conviva.com
.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210811005256/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
